Education
About Us
Working with TipRanks
Follow Us
Mckesson Corp. (MCK)
NYSE:MCK
MCK Analyst Ratings
Strong Buy
9 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MCK Stock 12 Month Forecast
Average Price Target
$723.00
▲(4.03% Upside)
| Highest Price Target$800.00 | Average Price Target$723.00 | Lowest Price Target$675.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
Reiterated
04/17/25
Bank of America Securities
Reiterated
04/16/25
CFRA
Downgraded
04/04/25
Deutsche Bank
Reiterated
04/03/25
Mizuho Securities
Reiterated
04/03/25
Morgan Stanley
Reiterated
04/02/25
Leerink Partners
Reiterated
04/02/25
Wells Fargo
Reiterated
03/14/25
TD Cowen
Reiterated
03/05/25
Robert W. Baird
Reiterated
02/18/25
Evercore ISI
$675
Buy
-2.88%
Downside
Reiterated
02/13/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWell.ca divestitures’ impact. We dug into these questions and remained confident MCK’s earnings power still intact in FY’26 despite the weakness in non-Pharma segments. For US Pharma, core pharma strength should continue driven by broad based specialty growth and solid utilization trends and we estimate ~8% core pharma growth in FY’26 (vs. ~10% in FY’25). In addition, timing-wise, both FCS and PRISM VISION deals should be closed by FY’26, and we estimate they contribute ~$190 MM and ~$95 MM AOI (pre-financing costs) respectively to FY’26 AOI. Lastly, Optum contract profitability lapping and GLP-1 growth should also be nice growth drivers to US Pharma. Overall, we expect US Pharma segment to deliver ~17% reported AOI growth, with ~8% growth from core and ~9% from M&A, Optum ramp and GLP-1s.
Jefferies
$715
Buy
2.88%
Upside
Reiterated
02/06/25
We maintain our positive view on MCK and point to the company's sustained ability to deliver on LT EPS growth goals (+12% to +14%) — which mgmt validated by providing commentary noting expectations for current fundamental strength to carry over into next yr — as reasons to justify multiple expansion that translates to stock upside from current levels (S&P 500 PE/G ratio of 1.8x, applied to MCK's growth rate mid-pt, suggests ~40% share price upside).
J.P. Morgan
$661→$708
Buy
1.87%
Upside
Reiterated
11/18/24
J.P. Morgan Sticks to Their Buy Rating for McKesson (MCK)
Barclays
$668
Buy
-3.88%
Downside
Reiterated
11/08/24
Barclays Remains a Buy on McKesson (MCK)
UBS
$670→$590
Buy
-15.11%
Downside
Reiterated
10/07/24
McKesson (MCK) PT Lowered to $590 at UBSUBS analyst Kevin Caliendo lowered the price target on McKesson (NYSE: MCK) to $590.00 (from $670.00) while maintaining a Buy rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
Reiterated
04/17/25
Bank of America Securities
Reiterated
04/16/25
CFRA
Downgraded
04/04/25
Deutsche Bank
Reiterated
04/03/25
Mizuho Securities
Reiterated
04/03/25
Morgan Stanley
Reiterated
04/02/25
Leerink Partners
Reiterated
04/02/25
Wells Fargo
Reiterated
03/14/25
TD Cowen
Reiterated
03/05/25
Robert W. Baird
Reiterated
02/18/25
Evercore ISI
$675
Buy
-2.88%
Downside
Reiterated
02/13/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWell.ca divestitures’ impact. We dug into these questions and remained confident MCK’s earnings power still intact in FY’26 despite the weakness in non-Pharma segments. For US Pharma, core pharma strength should continue driven by broad based specialty growth and solid utilization trends and we estimate ~8% core pharma growth in FY’26 (vs. ~10% in FY’25). In addition, timing-wise, both FCS and PRISM VISION deals should be closed by FY’26, and we estimate they contribute ~$190 MM and ~$95 MM AOI (pre-financing costs) respectively to FY’26 AOI. Lastly, Optum contract profitability lapping and GLP-1 growth should also be nice growth drivers to US Pharma. Overall, we expect US Pharma segment to deliver ~17% reported AOI growth, with ~8% growth from core and ~9% from M&A, Optum ramp and GLP-1s.
Jefferies
$715
Buy
2.88%
Upside
Reiterated
02/06/25
We maintain our positive view on MCK and point to the company's sustained ability to deliver on LT EPS growth goals (+12% to +14%) — which mgmt validated by providing commentary noting expectations for current fundamental strength to carry over into next yr — as reasons to justify multiple expansion that translates to stock upside from current levels (S&P 500 PE/G ratio of 1.8x, applied to MCK's growth rate mid-pt, suggests ~40% share price upside).
J.P. Morgan
$661→$708
Buy
1.87%
Upside
Reiterated
11/18/24
J.P. Morgan Sticks to Their Buy Rating for McKesson (MCK)
Barclays
$668
Buy
-3.88%
Downside
Reiterated
11/08/24
Barclays Remains a Buy on McKesson (MCK)
UBS
$670→$590
Buy
-15.11%
Downside
Reiterated
10/07/24
McKesson (MCK) PT Lowered to $590 at UBSUBS analyst Kevin Caliendo lowered the price target on McKesson (NYSE: MCK) to $590.00 (from $670.00) while maintaining a Buy rating.
Best Analysts Covering McKesson
Which Analyst Should I Follow If I Want to Buy MCK and Sell After:
1 Month
xxx
Success Rate
20/30 ratings generated profit
Average Return
+2.32%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.32% per trade.
3 Months
xxx
Success Rate
20/25 ratings generated profit
Average Return
+7.97%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +7.97% per trade.
1 Year
Success Rate
24/25 ratings generated profit
Average Return
+31.00%
reiterated a buy rating 25 days ago
Copying Michael Cherny's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +31.00% per trade.
2 Years
xxx
Success Rate
24/25 ratings generated profit
Average Return
+54.30%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 96.00% of your transactions generating a profit, with an average return of +54.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MCK Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
0
0
0
Buy
18
17
16
15
17
Hold
6
7
6
4
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
24
22
19
22
Each month's total comprises the sum of three months' worth of ratings.
MCK Financial Forecast
MCK Stock Forecast FAQ
What is MCK’s average 12-month price target, according to analysts?
Based on analyst ratings, Mckesson Corp.’s 12-month average price target is 723.00.
What is MCK’s upside potential, based on the analysts’ average price target?
Mckesson Corp. has 4.03% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MCK a Buy, Sell or Hold?
Mckesson Corp. has a consensus rating of Strong Buy which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.
What is Mckesson Corp.’s price target?
The average price target for Mckesson Corp. is 723.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $800.00 ,the lowest forecast is $675.00. The average price target represents 4.03% Increase from the current price of $695.
The highest analyst price target is $800.00 ,the lowest forecast is $675.00. The average price target represents 4.03% Increase from the current price of $695.
What do analysts say about Mckesson Corp.?
Mckesson Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of MCK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.